Nearly 12% of Americans Have Tried GLP-1 Based Weight Loss Medications

Nearly 12% of Americans have used GLP-1 medications like Ozempic for weight loss. The use is most common among women aged 50-64, with the drugs gaining popularity due to proven effectiveness and notable side effects such as nausea and diarrhea.
A recent study by RAND Corporation reveals that approximately 12% of the adult population in the United States has used GLP-1 receptor agonist drugs for weight reduction purposes. These medications, including well-known drugs like Ozempic, have gained popularity due to their significant role in facilitating weight loss, especially after numerous studies demonstrated their effectiveness. The survey examined a representative sample of 8,793 Americans, finding that about 11.8% have directly used these drugs, while another 14% expressed interest in trying them. Interestingly, usage rates vary across different demographics, with women aged 50 to 64 exhibiting the highest utilization. Among individuals aged 65 and above, the use was slightly higher in men, whereas women aged 30 to 49 were more than twice as likely to have taken these medications compared to their male counterparts.
The survey also highlighted common side effects experienced by users, predominantly nausea and diarrhea, affecting roughly half and one-third of the users, respectively. Since 2020, prescriptions for GLP-1 drugs have more than tripled, reflecting their rising prominence in weight management strategies. The increasing adoption of these drugs aligns with growing evidence of their efficacy in significant weight reduction, making them a cornerstone in contemporary obesity treatment.
Conducted during April and May of 2025, the study forms part of the largest and most recent research efforts to understand the extent of GLP-1 drug use in the U.S. This trend underscores a shift in weight loss approaches and highlights the importance of understanding both the benefits and side effects associated with these medications. The findings also point towards a demographic skew, with women in middle age leading the adoption of GLP-1 therapies.
Authors of the report include Robert Bozick, Shannon Donofry, and Katherine M. Rancaño, providing valuable insights into the evolving landscape of obesity treatment. This research emphasizes the growing influence of pharmacological solutions in weight management and the importance of monitoring side effects for safe use.
For further details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Evidence Supports Physical Activity as a Key Factor in Improving Cancer Survival Rates
New research shows that physical activity after a cancer diagnosis significantly improves survival rates across various cancer types, emphasizing the importance of stay active for cancer survivors.
New Insights into Gpr45 Gene Activity in Brain Cilia Reveal Potential Targets for Obesity Treatment
A groundbreaking study uncovers the role of Gpr45 gene activity in brain cilia, revealing new potential targets for obesity treatment by regulating appetite through cellular signaling pathways.
Health Authorities Issue Warning About Salmonella Outbreak Linked to Pistachio Cream
The CDC and FDA have issued a warning about a Salmonella outbreak linked to Emek-brand pistachio cream. Learn about the risks and safety precautions.
Preoperative Palliative Care Needs Lead to Higher Post-Surgery Healthcare Utilization in Older Adults with Serious Illness
Older adults with serious preoperative illnesses have significantly higher healthcare utilization and costs after elective surgery, highlighting the need for integrated palliative care strategies to improve outcomes.